ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

The Lancet Oncology Retracts Potti Paper, NEJM Doesn’t

February 4, 2011

In Brief: St. Jude, Yale to Get Bristol-Myers Grants; Five Named for New Young Scientists Awards

May 6, 1988

Research Teams Win Honors For Cancer Immunotherapy Work

October 15, 2010

In Brief: NCI to Extend Frederick contract To SAIC; Klausner, Gallin, Gail Elected to IOM

October 24, 1996

In Brief: Three More Comprehensive Centers May Be Names; Hawaii, Cleveland, Ohio State Lead List of 10

May 9, 1975

Advisors Approve CCOP, EDRN, Pediatric Brain Tumor Network Renewal

March 28, 2003